Olatec Therapeutics
New York, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Olatec Therapeutics is a privately held biopharmaceutical company founded in 2006 and headquartered in New York, USA. It is a clinical-stage leader focused on developing a platform of oral NLRP3 inflammasome antagonists to treat a broad spectrum of acute and chronic inflammatory diseases. The company's lead compound, dapansutrile (OLT1177®), is designed to selectively inhibit the NLRP3 inflammasome, thereby reducing the production of key pro-inflammatory cytokines IL-1β and IL-18.
Small Molecules